Results 141 to 150 of about 133,606 (242)

Efficacy and Safety of Second‐Line Lenvatinib After First‐Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background There is a paucity of data regarding the efficacy and safety of lenvatinib as a second‐line treatment following first‐line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre). Methods This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after ...
Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda, Aiko Tanaka, Kou Hashimoto, Tomoaki Emori, Yasutoshi Fujii, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Shinsuke Uchikawa, Nami Mori, Keiji Tsuji, Yosuke Suehiro, Keiichi Masaki, Michihiro Nonaka, Kenji Yamaoka, Yoshio Katamura, C. Nelson Hayes, Masataka Tsuge, Shiro Oka   +21 more
wiley   +1 more source

Prevalence of Active HCV Infection in Spain in 2022 Using Multiparameter Evidence Synthesis. [PDF]

J Viral Hepat
Thomadakis C, Gountas I, Gountas K, Nuño N, Brime B, Sendino R, Albillos A, Buti M, Crespo J, Berenguer J, Alonso S, de Santiago AD, Hernando V, Laguno M, Lens S, Diago M, Montes ML, García-Samaniego J, Morano L, Moreno JL, Navarro J, Romero-Gómez M, Santos L, Soriano R, Duffell E, Diaz A, Del Amo J, Nikolopoulos G.   +27 more
europepmc   +1 more source

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Background Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). However, validated criteria for predicting eligibility for conversion remain unclear. We investigated the utility of the recently proposed borderline
Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Hideki Onishi, Miwa Kawanaka, Akinobu Takaki, Kazuhiro Nouso, Kazuya Kariyama, Shinichiro Nakamura, Emi Tanaka, Toshifumi Tada, Tetsuya Yasunaka, Kenji Kuwaki, Junichi Toshimori, Shota Iwado, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Masahiro Sakata, Motoyuki Otsuka   +20 more
wiley   +1 more source

Improved Safety of Nucleic Acid Amplification Technology Combined With Serological Tests for Screening Blood Donors: A Systematic Review and Meta-Analysis. [PDF]

Rev Med Virol
Madeira HS, Brustolin AÁ, Almeida MEDS, Ribeiro MVG, Aguera RG, Jorge FA, Ghiraldi LD, Moreira DC, Lonardoni MVC, Bertolini DA, Peder LD, Silva CMD, Lera-Nonose DSSL, Ramos-Milaré ÁCFH, Teixeira JJV.   +14 more
europepmc   +1 more source

HCV NS4B protein; HCV NS5B polymerase [PDF]

Science-Business eXchange, 2013
openaire   +1 more source

Post‐to Pretreatment Ratio of Serum CXCL10 Level Predicts Short‐Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct‐Acting Antiviral Therapy

Hepatology Research, EarlyView.
The post‐to pretreatment serum CXCL10 ratio was independently associated with short‐term liver function outcome following HCV eradication in cirrhotic patients. ABSTRACT Aim The prognostic value of serum C‐X‐C motif chemokine ligand 10 (CXCL10) levels for liver function was investigated in hepatitis C virus (HCV)–infected patients with compensated or ...
Takanori Suzuki, Kentaro Matsuura, Yuki Tahata, Hayato Hikita, Masaru Enomoto, Atsunori Tsuchiya, Daiki Miki, Hiroshi Yatsuhashi, Hidekatsu Kuroda, Taro Yamashita, Hitoshi Yoshiji, Nobuharu Tamaki, Seiichi Mawatari, Hisamitsu Miyaaki, Yasuhiro Asahina, Yoichi Hiasa, Yoshihito Uchida, Yasunari Nakamoto, Taro Takami, Takahiro Kodama, Tetsuo Takehara   +20 more
wiley   +1 more source

Incidence and Characteristics of HBV Reactivation‐Related Events Following HBsAg Seroclearance: Long‐Term Follow‐up of a Population‐Based Cohort in Japan

Hepatology Research, EarlyView.
In a population‐based cohort in Japan, HBV reactivation‐related events were observed after HBsAg seroclearance, including one virologically confirmed hepatic flare occurring spontaneously without chemotherapy or immunosuppression. These findings indicate that HBsAg seroclearance does not always represent complete viral eradication, supporting the need ...
Kazumi Yamasaki, Satoshi Shirahama, Takahiro Yasaka, Shota Yamaguchi, Masashi Mizokami, Junko Tanaka, Hiroaki Okamoto, Hiroshi Yatsuhashi   +7 more
wiley   +1 more source

A Systematic Review and Narrative Synthesis of Factors Impacting Late Diagnosis of Chronic Hepatitis B and C. [PDF]

Health Sci Rep
Ibegu M, Keakabetse T, Nguyen ALT, Stephens N, de Graaff B.   +4 more
europepmc   +1 more source

VEGF‐Positive Mass‐Forming Intrahepatic Cholangiocarcinoma: New Subtype Based on Radiological and Molecular Pathological Analysis

Hepatology Research, EarlyView.
Radiological and molecular pathological investigation of hypervascular intrahepatic cholangiocarcinoma, typically a hypovascular tumor, revealed high VEGF expression, an increase in tumor‐associated arterial vessels, and a strong correlation with favorable prognosis.
Junya Tsuzaki, Naoto Kubota, Shigeyoshi Soga, Yasuhito Arai, Tatsuhiro Shibata, Minoru Esaki, Masahiro Jinzaki, Hidenori Ojima   +7 more
wiley   +1 more source

Health Benefits, Costs, and Cost-Effectiveness of Jail-Based Hepatitis C Elimination Strategies.

JAMA Intern Med
Zhu L, Magaldi LN, Wagh IA, Ennis ER, Reitsma MB, Kuncio DE, Addish E, Varghese SR, Furukawa NW, Honeycutt AA, Chen Y, Linas BP, Salomon JA.   +12 more
europepmc   +1 more source